Inadvertent Use of Long-Acting Insulin with Automated Insulin Delivery System in a Child with Newly Diagnosed Stage 3 Type 1 Diabetes: Case Report

Background Type 1 diabetes (T1D) is an autoimmune disease characterized by immune-mediated destruction of pancreatic β-cells, resulting in an insulin deficiency and hyperglycaemia. Intensive insulin therapy delivered through multiple daily injections or continuous subcutaneous insulin infusion (CSII) remains the cornerstone of treatment. Automated insulin delivery (AID) systems are increasingly used to optimize glycaemic control. Rapid-acting insulin analogues are recommended for continuous subcutaneous insulin infusion (CSII); however, treatment errors may occur, particularly during the early phase of T1D management, when caregivers are still developing experience in diabetes care. Case presentation We report the case of a 3.5-year-old child with newly diagnosed stage 3 T1D who initiated therapy using an AID system (mylife Ypso pump with CamAPS and Dexcom G6). Fifty-nine days after discharge, it was discovered that the child had been unintentionally receiving insulin glargine instead of lispro from the first home infusion set change due to caregiver confusion and continuation of prescriptions by the primary care physician. Retrospective analysis of two-week AID reports representing the earliest available datasets after recognition of the error demonstrated stable glycaemic control during the period of glargine use (time in range >80%) without diabetic ketoacidosis or severe hypoglycaemia. Limited hypoglycaemic episodes were observed only during the first days captured in the available reports. After reintroduction of lispro, insulin requirements decreased by approximately 40% while maintaining stable glycaemic control. Conclusions Unintentional use of insulin glargine in an AID system did not result in severe metabolic deterioration in this case, possibly due to partial remission and algorithm-driven insulin adjustments. This case highlights the importance of caregiver education, verification of insulin type, and multidisciplinary awareness to prevent medication errors in paediatric T1D management. It also illustrates how automated insulin delivery systems may partially compensate for unexpected pharmacokinetic deviations, highlighting both the resilience and safety considerations of AID therapy. To our knowledge, this is the first reported case of this type of insulin administration error involving inadvertent use of an incorrect insulin preparation.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-18
DOI
https://doi.org/10.21203/rs.3.rs-11258504/v1
Primary Topic
Diabetes Management and Research
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Inadvertent Use of Long-Acting Insulin with Automated Insulin Delivery System in a Child with Newly Diagnosed Stage 3 Type 1 Diabetes: Case Report

Magdalena Małachowska, P Jarosz-Chobot, M. Firek-Pędras, Karolina Klenczar
4 links
Research Square
Diabetes Management and Research
preprint

Inadvertent Use of Long-Acting Insulin with Automated Insulin Delivery System in a Child with Newly Diagnosed Stage 3 Type 1 Diabetes: Case Report

Magdalena Małachowska, P Jarosz-Chobot, M. Firek-Pędras, Karolina Klenczar
preprint en

Abstract

Background Type 1 diabetes (T1D) is an autoimmune disease characterized by immune-mediated destruction of pancreatic β-cells, resulting in an insulin deficiency and hyperglycaemia. Intensive insulin therapy delivered through multiple daily injections or continuous subcutaneous insulin infusion (CSII) remains the cornerstone of treatment. Automated insulin delivery (AID) systems are increasingly used to optimize glycaemic control. Rapid-acting insulin analogues are recommended for continuous subcutaneous insulin infusion (CSII); however, treatment errors may occur, particularly during the early phase of T1D management, when caregivers are still developing experience in diabetes care. Case presentation We report the case of a 3.5-year-old child with newly diagnosed stage 3 T1D who initiated therapy using an AID system (mylife Ypso pump with CamAPS and Dexcom G6). Fifty-nine days after discharge, it was discovered that the child had been unintentionally receiving insulin glargine instead of lispro from the first home infusion set change due to caregiver confusion and continuation of prescriptions by the primary care physician. Retrospective analysis of two-week AID reports representing the earliest available datasets after recognition of the error demonstrated stable glycaemic control during the period of glargine use (time in range >80%) without diabetic ketoacidosis or severe hypoglycaemia. Limited hypoglycaemic episodes were observed only during the first days captured in the available reports. After reintroduction of lispro, insulin requirements decreased by approximately 40% while maintaining stable glycaemic control. Conclusions Unintentional use of insulin glargine in an AID system did not result in severe metabolic deterioration in this case, possibly due to partial remission and algorithm-driven insulin adjustments. This case highlights the importance of caregiver education, verification of insulin type, and multidisciplinary awareness to prevent medication errors in paediatric T1D management. It also illustrates how automated insulin delivery systems may partially compensate for unexpected pharmacokinetic deviations, highlighting both the resilience and safety considerations of AID therapy. To our knowledge, this is the first reported case of this type of insulin administration error involving inadvertent use of an incorrect insulin preparation.

Research Square
Medical University of Silesia (PL), Górnośląskie Centrum Zdrowia Dziecka w Katowicach (PL)
Uniwersytet Śląski w Katowicach
Good health and well-being
Diabetes Management and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon